Six-micron paraffin sections of paraformaldehyde-fixed specimens of 24 ovarian benign and neoplastic specimens were assayed for tumor cell-specific oncogene expression by a sensitive, quantitative in situ hybridization technique with probes for 17 oncogenes, beta-actin, and E. coli beta-lactamase. In the benign, borderline, and invasive adenocarcinomas, multiple oncogenes, including neu, fes, fms, Ha-ras, trk, c-myc, fos, and PDGF-A chains, were expressed at significant levels relative to a housekeeping gene (beta-actin In some cell culture systems, serial transfection of morphologically benign primary cell lines with viral or cellular oncogenes can confer, stepwise, phenotypic traits characteristic of malignant cells [ 1, 2] . Such observations have inspired hypotheses that a similar incremental progression of cellular oncogene activation (mutation, aberrant over-or underexpression, and so on) occurs during the development of spontaneous neoplasms [3] [4] [5] [6] [7] . Ovarian epithelial neoplasms are a system well-suited for testing such hypotheses, since they encompass a broad spectrum of lesions, ranging from benign hyperproliferative serous and mucinous adenomatous cysts, serous and mucinous adenomas of borderline malignant potential to invasively malignant welldifferentiated, moderately differentiated, and poorly differentiated serous, mucinous, 
including neu, fes, fms, Ha-ras, trk, c-myc, fos, and PDGF-A chains, were expressed at significant levels relative to a housekeeping gene (beta-actin). In the mixed-Mullerian tumors, a rather different pattern of oncogene expression was observed, characterized primarily by In some cell culture systems, serial transfection of morphologically benign primary cell lines with viral or cellular oncogenes can confer, stepwise, phenotypic traits characteristic of malignant cells [ 1, 2] . Such observations have inspired hypotheses that a similar incremental progression of cellular oncogene activation (mutation, aberrant over-or underexpression, and so on) occurs during the development of spontaneous neoplasms [3] [4] [5] [6] [7] . Ovarian epithelial neoplasms are a system well-suited for testing such hypotheses, since they encompass a broad spectrum of lesions, ranging from benign hyperproliferative serous and mucinous adenomatous cysts, serous and mucinous adenomas of borderline malignant potential to invasively malignant welldifferentiated, moderately differentiated, and poorly differentiated serous, mucinous, and endometroid adenocarcinomas, and include less common histologies such as mixed-Mullerian (mixed mesodermal) tumors, and others [8] [9] [10] . Clinical presentations also vary and range from small lesions confined within the ovarian capsule to aggressively malignant neoplasms which have disseminated throughout the peritoneal cavity and metastasized to distant visceral sites. At least for the adenocarcinomas, clinical extent of disease and histologic grade at presentation correlate very strongly with outcome [8] [9] [10] . We anticipated, therefore, that studies of cellular changes of oncogene expression in ovarian neoplasia would provide us with valuable information on those relationships which exist between prognostically important clinical and pathologic characteristics and qualitative and quantitative changes in tumor cellspecific oncogene expression.
In 1989, over 30 different genes have been identified as potential oncogenes [6, 7, [11] [12] [13] . Most previously published reports have focused on the importance of the expression of a single oncogene or oncogene class in tumor tissue or tumor-derived cell lines [14] [15] [16] [17] . In this paper, we report the use of a sensitive and quantitative in situ hybridization technique [18] [19] [20] [21] [22] to assay levels of expression of 17 different oncogenes in 24 ovarian benign and neoplastic specimens. This quantitative data was subjected to statistical analyses, revealing many interesting relationships, some of which link high-grade, high-stage presentations to genes not otherwise implicated in the biology of epithelial neoplasms.
MATERIALS AND METHODS Tissue Specimen Accrual, Preparation, and in Situ Hybridization (ISH)
All tissue specimens were obtained from patients of the Hunter Radiation Therapy and Ob/Gyn clinics of the Yale University School of Medicine, in accordance with Yale HIC protocol 3303. Small biopsies (maximum, -3 mm thick) of ovarian neoplastic or benign tissues were obtained during therapeutic or diagnostic procedures (by PES, EIK, SKC, and JTC) and placed into freshly prepared PGP fixative (4 percent paraformaldehyde, 0.5 percent glutaraldehyde, 0.1 M Na-phosphate [pH 7.5]) within one to two minutes of harvest. Fixation was continued for four to six hours. Specimens were processed for embedding in paraffin, six-micron sections cut, prepared for, and carried through in situ hybridization and nuclear track emulsion autoradiography, as has been described elsewhere [18] [19] [20] [21] [22] [23] [24] . Probes for ISH were prepared by appropriate restriction digest of chimeric plasmids with cloned oncogenes, labeled with 35S-dCTP by random primer extension [25] , using alpha-35S-labeled dCTP to give specific activities averaging 5 x 108 dpm/mcg DNA [26] , and were complementary to coding sequences of beta-actin [27] (PstI), and enterobacterial beta lactamase [28] (EcoRI, PstI), c-myc [29] (third exon; Clal, EcoRI), N-myc [30] (third exon; AccI, Aval), L-myc [31] (second and third exon; SmaI, EcoRI), c-fos [32] (NcoI, XhoI), myb [33] (KpnI, XbaI), p53 [34] (EcoRI, BglII), Ha-ras [35] (SstI, PstI), Ki-ras [36] (EcoRI), N-ras [37] (SalI, NcoI), sis [38] (PstI, XbaI), PDGF-A chain [39] (SstI, Hindlll), erbB [40] (BamHI), neu [41] (BamHI),fes [42] (PstI),fms [43] (PstI), ros [44] (EcoRI, PvuII), and trk [45] (NcoI, EcoRI). Sections of confluent monolayers of BeWo cells [46] (grown in Weymouth's + 10 percent fetal calf serum, 370C, 5 percent C02) were processed with each experimental run as positive controls. In our experiments, BeWo cells show consistently elevated levels of expression of c-myc, fis, andfos complementary mRNAs and were useful positive controls (see Fig. 1 ) [47, 48] .
Non-neoplastic ovarian tissues are included as negative controls (e.g., cases 1 and 2). The hematoxylin-and eosin-stained ISH autoradiograms are analyzed by light microscopy and grain counts quantitated with the aid of the Olympus Corporation Cue 2 VISION Image Analysis System. Randomly chosen fields of epithelium or stroma are visualized and grain counts quantified with the Cue 2 Image Analysis System, which automatically resolves black silver grains from cell features to size and count total silver grains for each -7,750-micron2 (100x) oil immersion field. Ideally, enough fields are viewed and silver grains counted for a specific histologic feature (e.g., tumor epithelium, tumor stroma, and adjacent normal tissue) to yield a total of 500-1,000 grains. Grain counts per field are converted to hybrids per micron3 by multiplicative factors' which take into account section thickness, size and specific activity of probes, exposure duration, and microscope field size. Pearson's correlation test was applied to the tabulated data for each probe with the aid of the PRODAS Professional Database Analysis System, Version 3.2 (Conceptual Software, Houston, TX) to yield R-values and p-values of the pairwise comparisons of oncogene and actin mRNA hybrids per micron3 with each other, FIGO grade (0-3) and FIGO stage (0-IV). Borderline lesions were assigned a nominal grade of 0.5 to reflect their histologic status intermediate between benign (grade 0) and well-differentiated, invasive (grade 1) adenocarcinomas [8, 49] . RESULTS Quantitative in situ hybridization analyses were carried out with specific probes for beta-actin [27] , pBR322 [28] , and 17 oncogenes [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] on two benign, three borderline, one grade 1 (mucinous), six grade 2 (serous), seven grade 3 (serous and poorly differentiated) adenocarcinomas, and five anaplastic mixed-Mullerian tumors (MMT) of the ovary. Representative data sets of hybrids per micron3 are presented for the BeWo human choriocarcinoma cell line [46] and the tumor epithelium and stroma of a grade 3 papillary serous adenocarcinoma of the ovary (Fig. 1) . For the adenocarcinoma, we demonstrate the localization of c-myc, fos, and fms mRNA to tumor epithelium but not stroma.
Similar data for actin and 17 oncogene probes are presented for all 24 specimens in Tables 1 and 2 . T-test comparison of hybrid values for the 14 adenocarcinomas to the five benign and borderline malignant neoplasms identify onlyfms and PDGF-A hybrid levels as significantly higher in the invasive adenocarcinomas, although several other genes (neu, fes, Ha-ras, trk, c-myc, as well as fis and PDGF-A) are expressed at higher levels in the neoplastic epithelial cells than a housekeeping gene, beta-actin. For the small collection of MMTs,fos and myc were both expressed at higher levels than actin, while higher expression of fos transcripts differentiated the MMTs from the benign and borderline neoplasms. ' For example, for a 1 kb probe labeled to 5 x Io8 dpm/,ug specific activity, one hybrid emits -1.4 "S beta particles after a 48-hour (our standard) exposure to yield one silver grain in a photoemulsion whose detection efficiency was 100 percent. Our estimates of hybrids per micron2 and hybrids per 100 x field are presented in terms of such an ideal emulsion, since the absolute efficiency of NTB-2 emulsion for isotopes such as 35S is not precisely known. Basic physical dosimetric constraints, however, limit photoemulsion detection efficiency for "S-beta particles to -10 percent (and conceivably much less), and, hence, one grain could represent the beta emissions of seven or more radiolabeled hybrids and the hybrids per cubic micron values which we derive actually underestimate the true number of radioactive hybrids present. In Table 3 , we present the statistically significant pairwise correlations observed for the data summarized in Tables 1 and 2 for the five benign and borderline and 14 ovarian adenocarcinoma specimens. Of particular interest are the strong correlations seen between FIGO histologic grade with levels of fms, PDGF-A, fos, and c-myc hybrids; the significant correlation of stage with levels offms hybrids; and the strong correlations offms and PDGF-A levels with each other and withfos and c-myc hybrid levels. Other less obvious but significant correlations between different oncogene probes are also revealed by this analysis and summarized in Table 3 . When the five mixed-Mullerian tumors are compared as a group to the five benign and borderline neoplasms and the 14 ovarian adenocarcinomas, levels of sis (PDGF-B chain) expression were found to correlate significantly with the presence of MMT histologic features (R-value, 0.50801; p-value, 0.02638) whilefms (R-value, -0.40290; p-value, 0.08721) and PDGF-A (R-value, -0.43548; p-value, 0.06328) expression correlated nearly significantly with their absence.
Ras oncogene mRNA expression was also noted in the tumor epithelium of most of the specimens but did not significantly correlate with either tumor grade or stage, nor 17 oncogenes studied, however, onlyfms hybrid levels correlate strongly with both high FIGO clinical stage and/or high histologic grade, which are the two clinicopathologic features of ovarian adenocarcinomas most strongly predictive of aggressive behavior and poor outcome [8] [9] [10] . Sis expression correlated with the presence of mixed-Mullerian as opposed to adenocarcinoma histologic features, an observation which is not wholly unexpected, since the sis gene product (PDGF-B chain) has been implicated by others as an autocrine mitogen in sarcomatous neoplasms [50] . Levels of fos transcripts (a gene expressed at higher levels in many types of rapidly proliferating cells) distinguished these aggressive, but rare, neoplasms from benign or borderline specimens.
Many statistically significant correlations were observed between levels of expression of different mRNAs (Table 3) , and many are not surprising in the context of what is now known about the physiology of the genes involved. Thus, strong correlations should be and were observed between levels offos and c-myc hybrids even though the probes themselves have no homology, since both genes are known to be expressed together in rapidly proliferating cells. Likewise, the correlations between the src family oncogenes erbB, neu, ros, fms with fos and c-myc are reasonable if the erbB, neu, ros, and fns protein kinases and their ligands play some role in the control of ovarian epithelial cell proliferation [51, 52] . Indeed, the presence of such biologically reasonable correlations helps to provide valuable internal confirmation of the consistency and validity of our in situ hybridization data and its statistical analyses.
Other correlations, such as those found for different src family oncogenes with each other, may be a consequence of low-level homology and cross-hybridization between the probes for one oncogene and the mRNA of another; however, no evidence of significant correlation or cross-hybridization was even observed for the related (Ha-, Ki-, and N-ras and c-, L-, and N-myc) gene probes to suggest that the hybridization conditions used in our experiments were not adequately stringent. Hence, the strong correlations observed for pairs of different src family oncogene probes may indicate coordinate expression of multiple growth factor receptors (erbB, neu,fis, ros, trk) by the tumor epithelial cells of our specimens, an interpretation consistent with the strong correlations which we observed between expression of some of these src family genes and expression of c-myc andfos (refer to Table 3 ).
The interpretation of some of the correlations (such as that offes with myb, sis with Ki-ras, c-myc with N-ras, n-myc with Ha-ras, n-myc with p53 and Ha-ras, and N-ras with neu) is not, however, apparent. They suggest possible coordinate expression of otherwise unrelated genes and may help to identify possible pathways of signal transduction in ovarian carcinoma cells involving co-expressed growth factor receptors, ras-encoded GTP-binding proteins, and nuclear protein oncogenes.
The observed correlation between fis with both grade and stage for ovarian adenocarcinomas warrants further discussion. Thefms oncogene, first characterized in a feline retrovirus, is now known to code for the receptor for macrophage colony stimulating factor M-CSF or CSF-1, a mitogen, chemoattractant, and phenotypic activator of tissue macrophages [53, 54] and trophoblast (which expresses high levels of the c-fis gene) with important roles in wound healing, immune response, and the implantation and development of the human placenta. Two other fms-related genes have also been identified, c-kit and PDGF-receptor, both of which are homologous to fms primarily in the 3' protein domain with much less homology in 5' extracellular sequences. If thefms gene expressed in ovarian neoplasms is mutant or rearranged with a constitutively active protein kinase (as is the v-fms protein) [55, 56] , other physiologic changes may not be needed to produce uncontrolled cell growth and a malignant cell phenotype. Southern blot hybridization with probes derived from the 3' and 5' halves of the human c-fms gene for three benign and 23 malignant ovarian specimens failed to disclose any significant rearrangements of c-fms genomic structure (data not shown), while Northern blot, cDNA PCR, immunohistochemical studies, and immunological studies (to be submitted elsewhere) suggest the expression of a normal or near-normal c-fms mRNA and protein by ovarian adenocarcinoma cells both in vivo and in vitro.
Claims for importance for fms (or a closely related gene) in non-hematopoietic neoplasms are not totally without precedent. Walker et al. [57] have recently reported that overexpressed length fis-complementary transcripts were observed in tumorigenic cell lines derived from MNNG-or gamma ray-mutagenized primary tracheal epithelial cells. Similarly, Feldman and Eisenbach [58] have reported the association of the expression of a fms-complementary transcript with metastatic phenotype in several mouse carcinoma cell lines, while we have reported in vivo fms transcript expression in many endometrial and breast carcinomas. If tumor cells do indeed express a normal or near-normal c-fms gene product, then a source of CSF-1 would be necessary to allow this receptor to exert phenotypic consequences on tumor cells which express it. CSF-1 (M-CSF) [53, 54, 59 ] is present in many tissues where it is synthesized by proliferating fibroblasts, activated macrophages, and other mesenchymal cells, and it is possible that the ubiquitous low levels of this mitogen are adequate to stimulate the proliferation of cells with high levels of M-CSF receptor. Such stromal cell production of CSF-1 could be facilitated by tumor cell synthesis of stroma mitogens such as PDGF-A, whose expression is strongly linked to tumor grade and expression of fms in our ovarian adenocarcinoma specimens (Table 1) ; however, stromal CSF-1 production is not the only available source for this cytokine in ovarian carcinoma patients. We, and others, have reported ovarian tumor cell line expression of CSF-1 in vitro and have observed markedly elevated plasma CSF-1 levels in ovarian carcinoma patients with active disease [60] . Such high levels of circulating cytokine may facilitate tumor growth and spread to metastatic site, a possibility under active investigation. Less complete information in breast, lung, and endometrial adenocarcinoma supports the hypothesis that similar CSF-1 /CSF-1 receptor para-and autocrine interactions may be important in the development and progression of aggressive epithelial malignancies at other sites. This mechanism, in and of itself, does not exclude or diminish potentially important roles for the neu, erbB, ros, or ras oncogenes in ovarian adenocarcinomas; it merely suggests that their expression is not closely linked to those high-grade, high-stage presentations prognostic of poor clinical outcome.
One particular gene, neu, has been the focus of much controversy concerning its role in determining the prognosis of breast and, perhaps, ovarian carcinoma patients [61, 62] and is worthy of further discussion here. We have observed that levels of neu expression (like PDGF-A and fms) strongly correlate with c-fos andmyc expression (Table 2) in ovarian (as well as breast [21] ) carcinomas even though levels of neu expression in benign and borderline lesions are not significantly different from those observed in invasively malignant neoplasms (Table 2 ). In addition, we observed statistically significant correlations between levels of neu and fms expression in both ovarian and breast neoplasms. Such observations have led us to predict that the neu gene product is in some way involved in the control of epithelial cell proliferation in the ovary and breast and that it is at least co-expressed (and may interact) with thefms gene product. We are, however, still wary of any attempts [61] to relate levels of neu gene expression with prognosis in ovarian cancer, since, in our analysis, neu expression levels did not correlate significantly with either tumor grade or stage-both of which are extremely strong prognosticators of short-and long-term outcome in ovarian carcinoma patients treated with either standard chemotherapy or radiotherapy [8] [9] [10] .
Likewise, in many human tumors, expression, and often overexpression, of a mutated ras oncogene is recognized to be an important step in the development of malignant neoplasms [14] [15] [16] . In fact, nearly all of our borderline and invasively malignant specimens show significant levels of ras-complementary hybrids (refer to Table 1 ), and several of our anaplastic ovarian MMT specimens even show significant hybridization to more than one ras probe. Our in situ hybridization techniques are not able to discriminate mutant from wild-type ras gene expression in our specimens, but we hope that further refinements of in situ hybridization and in situ transcription and PCR techniques [63] and the recent development of antibodies able to discriminate mutant from wild-type ras proteins [64] will help us to elucidate the role these overexpressed ras oncogenes play in determining the malignant phenotypes of ovarian adenocarcinoma cells.
